These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 11498595)
1. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595 [TBL] [Abstract][Full Text] [Related]
2. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs. Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633 [TBL] [Abstract][Full Text] [Related]
3. The antigenic structure of the HIV gp120 envelope glycoprotein. Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684 [TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016 [TBL] [Abstract][Full Text] [Related]
5. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1. Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988 [TBL] [Abstract][Full Text] [Related]
6. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12. Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780 [TBL] [Abstract][Full Text] [Related]
7. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580 [TBL] [Abstract][Full Text] [Related]
8. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063 [TBL] [Abstract][Full Text] [Related]
9. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775 [TBL] [Abstract][Full Text] [Related]
10. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Pantophlet R; Wilson IA; Burton DR Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540 [TBL] [Abstract][Full Text] [Related]
11. Structural studies of human HIV-1 V3 antibodies. Stanfield RL; Wilson IA Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977 [TBL] [Abstract][Full Text] [Related]
13. B cell antigenic site mapping of HIV-1 glycoproteins. Neurath AR Chem Immunol; 1993; 56():34-60. PubMed ID: 8452653 [No Abstract] [Full Text] [Related]
14. AIDS/HIV. A boost for HIV vaccine design. Burton DR; Weiss RA Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840 [No Abstract] [Full Text] [Related]
15. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968 [TBL] [Abstract][Full Text] [Related]
16. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
17. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856 [TBL] [Abstract][Full Text] [Related]
18. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. Julien JP; Bryson S; Nieva JL; Pai EF J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005 [TBL] [Abstract][Full Text] [Related]
19. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. McInerney TL; McLain L; Armstrong SJ; Dimmock NJ Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055 [TBL] [Abstract][Full Text] [Related]
20. AIDS/HIV. Converging on an HIV vaccine. Korber B; Gnanakaran S Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189 [No Abstract] [Full Text] [Related] [Next] [New Search]